Estradiol  - novelty or standard in vaginal therapy?

Edyta Wlaźlak; Grzegorz Surkont; Jacek Suzin

Abstract

5/2004 vol. 3

Estradiol - novelty or standard in vaginal therapy?

Edyta Wlaźlak

,

Grzegorz Surkont

,

Jacek Suzin

Online publish date: 2004/10/22

View full text

AMA

Wlaźlak E, Surkont G, Suzin J. Estradiol - novelty or standard in vaginal therapy?. Menopause Review/Przegląd Menopauzalny. 2004;3(5):50-56.

APA

Wlaźlak, E., Surkont, G., & Suzin, J. (2004). Estradiol - novelty or standard in vaginal therapy?. Menopause Review/Przegląd Menopauzalny, 3(5), 50-56.

Chicago

Wlaźlak, Edyta, Grzegorz Surkont, and Jacek Suzin. 2004. "Estradiol - novelty or standard in vaginal therapy?". Menopause Review/Przegląd Menopauzalny 3 (5): 50-56.

Harvard

Wlaźlak, E., Surkont, G., and Suzin, J. (2004). Estradiol - novelty or standard in vaginal therapy?. Menopause Review/Przegląd Menopauzalny, 3(5), pp.50-56.

MLA

Wlaźlak, Edyta et al. "Estradiol - novelty or standard in vaginal therapy?." Menopause Review/Przegląd Menopauzalny, vol. 3, no. 5, 2004, pp. 50-56.

Vancouver

Wlaźlak E, Surkont G, Suzin J. Estradiol - novelty or standard in vaginal therapy?. Menopause Review/Przegląd Menopauzalny. 2004;3(5):50-56.

Authors present review of articles about the use of vaginal tablets containing 25 µg of 17β-estradiol in the treatment of urogynecological complaints resulting from estrogen deficiency in peri- and postmenopausal women. Data shows that dose of 25 µg of 17β-estradiol does not have clinically significant systemic activity. Till now, if properly used, vaginal tablet containing 25 µg of 17β-estradiol does not show stimulating activity on endometrium. Authors consider that medicaments containing estradiol ad estriol are both standards in modern vaginal estrogen therapy. Vaginal tablet containing 17β-estradiol are noticed by most of the patients as more comfortable ad hygienic than vagitories and creams.